Funder: Eli Lilly and Company
Due Dates: February 15, 2026: Full proposal submission deadline for RFP: Efficacy of Lebrikizumab in patients with fibrosing skin conditions | February 15, 2026: Full proposal submission deadline for RFP: How does lebrikizumab impact post-inflammatory dyspigmentation as measured by the PDCA-Derm™ scale in patients with moderate to severe atopic dermatitis?
Funding Amounts: Funding and/or study drug support; specific award size and duration not stated—varies by project and RFP.
Summary: Supports investigator-initiated clinical research aligned with Lilly’s posted RFPs in dermatology, focusing on lebrikizumab.